Sonorous NV’s BossStent to Treat Symptomatic Cerebral Venous Diseases Used in First Patients in North America

December 16, 2022—Sonorous NV, Inc. announced that the company’s BossStent device, which is designed to treat patients with symptomatic cerebral venous diseases, was used in the first patients in North America.

The company will initiate clinical trials in Q2 2023 to obtain European and United States regulatory approvals, which the company aims to achieve in Q1 2024. Sonorous NV noted that it received its initial seed funding in Q1 of 2022 and developed the product to achieve first clinical use in less than 1 year.

According to Sonorous NV, the single-use, implantable device acts as an endoluminal prothesis that is placed into a cerebral venous sinus stenosis to normalize blood flow and pressure gradients causing pulsatile tinnitus, idiopathic intracranial hypertension, and papilledema.

The initial cases in North America were performed by neurosurgeon Vitor Mendes Pereira, MD, who is the Director of Endovascular Research and Innovation at the St. Michael’s Hospital in Toronto, Canada.

“The BossStent Sonorous NV device produced excellent clinical results,” commented Dr. Mendes Pereira in the company’s press release. “It offers a breakthrough solution for patients with symptomatic cerebral venous diseases associated with venous sinus stenosis who require interventional therapy. Knowing such a solution exists places both patients and physicians at ease and will create opportunities in the future for patients who are experiencing these debilitating symptoms.”